These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 9460716)
41. Correlation of p63 protein expression with histological grade of meningiomas: an immunohistochemical study. Mittal S; Jain D; Roy S; Mehta VS Int J Surg Pathol; 2012 Aug; 20(4):349-54. PubMed ID: 22287651 [TBL] [Abstract][Full Text] [Related]
42. MIB-1 staining index of pediatric meningiomas. Sandberg DI; Edgar MA; Resch L; Rutka JT; Becker LE; Souweidane MM Neurosurgery; 2001 Mar; 48(3):590-5; discussion 595-7. PubMed ID: 11270550 [TBL] [Abstract][Full Text] [Related]
43. Cyclin E1 expression and malignancy in meningiomas. Pereira BJA; Santana Júnior PA; de Almeida AN; Cavalcante SG; de Melo KCM; de Aguiar PHP; Paiva WDS; Oba-Shinjo SM; Marie SKN Clin Neurol Neurosurg; 2020 Mar; 190():105647. PubMed ID: 31945623 [TBL] [Abstract][Full Text] [Related]
44. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas. Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125 [TBL] [Abstract][Full Text] [Related]
45. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases. Roser F; Samii M; Ostertag H; Bellinzona M Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263 [TBL] [Abstract][Full Text] [Related]
46. Progesterone receptor, bc1-2 and bax expression in meningiomas. Verheijen FM; Donker GH; Viera CS; Sprong M; Jacobs HM; Blaauw G; Thijssen JH; Blankenstein MA J Neurooncol; 2002 Jan; 56(1):35-41. PubMed ID: 11949825 [TBL] [Abstract][Full Text] [Related]
47. Clinicopathological variables, immunophenotype, chromosome 1p36 loss and tumour recurrence of 247 meningiomas grade I and II. Ruiz J; Martínez A; Hernández S; Zimman H; Ferrer M; Fernández C; Sáez M; López-Asenjo JA; Sanz-Ortega J Histol Histopathol; 2010 Mar; 25(3):341-9. PubMed ID: 20054806 [TBL] [Abstract][Full Text] [Related]
48. [Atypical, aplastic, and unusual meningiomas. Morphology and incidence in 300 consecutive cases]. Buccoliero AM; Caldarella A; Taddei A; Di Lorenzo N; Gallina P; Mennonna P; Ammannati F; Taddei GL Pathologica; 2003 Apr; 95(2):83-7. PubMed ID: 12768876 [TBL] [Abstract][Full Text] [Related]
49. Overexpression of RLIP76 Required for Proliferation in Meningioma Is Associated with Recurrence. Fan SY; Jiang JD; Qian J; Lu YC; Hu GH; Luo C; Hou WD; Wang Q PLoS One; 2015; 10(5):e0125661. PubMed ID: 25993541 [TBL] [Abstract][Full Text] [Related]
50. WHO grade related expression of TRAIL-receptors and apoptosis regulators in meningioma. Koschny R; Krupp W; Xu LX; Mueller WC; Bauer M; Sinn P; Keller M; Koschny T; Walczak H; Bruckner T; Ganten TM; Holland H Pathol Res Pract; 2015 Feb; 211(2):109-16. PubMed ID: 25481563 [TBL] [Abstract][Full Text] [Related]
51. Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Mawrin C; Sasse T; Kirches E; Kropf S; Schneider T; Grimm C; Pambor C; Vorwerk CK; Firsching R; Lendeckel U; Dietzmann K Clin Cancer Res; 2005 Jun; 11(11):4074-82. PubMed ID: 15930342 [TBL] [Abstract][Full Text] [Related]
52. [Meningiomas: new prognostic factors]. Sanz Esponera J An R Acad Nac Med (Madr); 2007; 124(2):319-32; discussion 330-2. PubMed ID: 18069599 [TBL] [Abstract][Full Text] [Related]
53. Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas. Konstantinidou AE; Korkolopoulou P; Kavantzas N; Mahera H; Thymara I; Kotsiakis X; Perdiki M; Patsouris E; Davaris P Histol Histopathol; 2003 Jan; 18(1):67-74. PubMed ID: 12507285 [TBL] [Abstract][Full Text] [Related]
54. Histopathology and MIB-1 labeling index predicted recurrence of meningiomas: a proposal of diagnostic criteria for patients with atypical meningioma. Ho DM; Hsu CY; Ting LT; Chiang H Cancer; 2002 Mar; 94(5):1538-47. PubMed ID: 11920512 [TBL] [Abstract][Full Text] [Related]
55. [Estrogen and progesterone receptors in meningiomas: immunohistochemical (Mib-1, p53) and clinico-morphological correlations]. Taddei GL; Caldarella A; Raspollini MR; Taddei A; Buccoliero AM Pathologica; 2002 Feb; 94(1):10-5. PubMed ID: 11912872 [TBL] [Abstract][Full Text] [Related]
56. Proliferating cell nuclear antigen (PCNA) in atypical and malignant meningiomas. Zimmer C; Gottschalk J; Cervos-Navarro J; Martin H; Beil M; Jautzke G Pathol Res Pract; 1992 Dec; 188(8):951-8. PubMed ID: 1363764 [TBL] [Abstract][Full Text] [Related]
57. MIB1 staining index and scoring of histologic features in meningioma. Indicators for the prediction of biologic potential and postoperative management. Ohta M; Iwaki T; Kitamoto T; Takeshita I; Tateishi J; Fukui M Cancer; 1994 Dec; 74(12):3176-89. PubMed ID: 7982181 [TBL] [Abstract][Full Text] [Related]
58. Correlation of DNA content and nucleomorphometric features with World Health Organization grading of meningiomas. Grunewald JP; Röhl FW; Kirches E; Dietzmann K Mod Pathol; 1998 Feb; 11(2):216-23. PubMed ID: 9504694 [TBL] [Abstract][Full Text] [Related]
59. Loss of tumor suppressor in lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced patient survival. Surace EI; Lusis E; Murakami Y; Scheithauer BW; Perry A; Gutmann DH J Neuropathol Exp Neurol; 2004 Oct; 63(10):1015-27. PubMed ID: 15535129 [TBL] [Abstract][Full Text] [Related]
60. Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study. Caltabiano R; Barbagallo GM; Castaing M; Cassenti A; Senetta R; Cassoni P; Albanese V; Lanzafame S J Neurosurg Sci; 2013 Jun; 57(2):139-51. PubMed ID: 23486338 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]